Welcome to our dedicated page for Xencor news (Ticker: XNCR), a resource for investors and traders seeking the latest updates and insights on Xencor stock.
Xencor, Inc. develops engineered antibody therapeutics for cancer and autoimmune diseases using its XmAb technology platform and related antibody-engineering formats. News about XNCR commonly covers clinical and preclinical updates for XmAb drug candidates, including TL1A programs such as XmAb942 and XmAb412, T-cell engaging bispecific antibodies such as XmAb819 and XmAb541, and presentations of data at medical meetings.
Recurring company updates also include quarterly financial results, research-and-development priorities, collaboration and licensing activity, intellectual-property developments tied to Xtend Fc domain technology, and royalty matters involving partner-marketed medicines such as Ultomiris.
SpikImm's SPK001, a monoclonal antibody for COVID-19 prevention, has been awarded "national priority" status by the French government. In Phase 1 trials, it showed excellent tolerance among initial cohorts. Targeting immunocompromised patients, the drug could address a significant market need, with around 300,000 patients in France alone. SpikImm plans to advance to a Phase 2 trial by Q1 2023 and may seek early access approval in Q2 2023. The company has partnered with Xencor to enhance the antibody's efficacy.
Xencor, Inc. (NASDAQ:XNCR) announced seven poster presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer from November 10-12, 2022, in Boston. Key highlights include data from a Phase 2 study of vudalimab, a PD-1 x CTLA-4 bispecific antibody, plus chemotherapy for metastatic castration-resistant prostate cancer (mCRPC). Other studies involve XmAb819 for renal cell carcinoma and various preclinical programs. The findings will enhance understanding of these treatments and their potential impact on cancer therapies.
Xencor, Inc. (NASDAQ:XNCR) announced the appointment of Dr. Nancy Valente to its board of directors, bringing over 20 years of experience in late-stage biopharmaceutical development, particularly in oncology. Dr. Valente previously held a senior position at Genentech, where she played a critical role in the launch of several therapies. Concurrently, Yujiro S. Hata, a director since 2015, resigned from the board. The leadership change is expected to enhance Xencor's strategic direction as it continues developing engineered antibodies for cancer and autoimmune diseases.
Xencor, Inc. reported its financial results for Q2 2022, with total revenue of $30.2 million, down from $67.4 million in Q2 2021. The company recognized $22.1 million in royalties from Vir Biotechnology and $6.7 million from Alexion Pharmaceuticals. R&D expenses declined to $47.1 million from $49.5 million year-over-year, while G&A expenses increased to $11.1 million. Xencor posted a net loss of $34 million, or $(0.57) per share, compared to a net income of $52.2 million, or $0.87 per share, in Q2 2021. The company anticipates having sufficient cash to fund operations through 2025.
On August 2, 2022, Caris Life Sciences and Xencor, Inc. (NASDAQ: XNCR) announced a strategic agreement to develop XmAb® bispecific antibodies targeting novel cancer treatment options. Caris will utilize its proprietary discovery platform to identify these targets, while Xencor will leverage its XmAb engineering technology. Xencor will receive exclusive options to commercialize products related to three targets, alongside a payment of up to $120 million in milestones and royalties. This collaboration aims to address the need for new therapeutic targets in oncology.
Xencor, Inc. (NASDAQ: XNCR) will announce its second quarter 2022 financial results post-market on August 3, 2022. A conference call and webcast will take place at 4:30 p.m. ET to discuss these results alongside a corporate update. The webcast will be accessible on the company's investor website and available for archiving for 30 days.
Xencor specializes in developing engineered antibodies and cytokines aimed at treating cancer and autoimmune disorders, with over 20 candidates in clinical development using its advanced XmAb® technology.
Xencor, Inc. (NASDAQ:XNCR) recently announced initial data from the Phase 1 clinical study of XmAb104, a bispecific antibody targeting PD-1 and ICOS, in patients with advanced solid tumors. Results will be presented at the ASCO Annual Meeting on June 5, 2022. The study aims to assess safety and tolerability while determining the maximum tolerated dose (MTD). With 62 patients treated, XmAb104 showed a distinct safety profile, and two confirmed partial responses were observed. The recommended dose for further study is 10 mg/kg, suggesting promising therapeutic potential.
Xencor, a clinical-stage biopharmaceutical company, reported strong Q1 2022 results, highlighting revenues of $85.5 million, up from $34 million in Q1 2021. The company has a robust financial position with $683.6 million in cash and marketable securities. Key developments include dosing the first patient in a Phase 2 trial for plamotamab. However, Xencor foresees a decline in future royalty revenues from sotrovimab. Overall, the company is advancing multiple clinical programs while maintaining a net income of $23.6 million or $0.39 per diluted share.
Xencor, Inc. (NASDAQ: XNCR), a biopharmaceutical company focused on engineered antibodies and cytokines, will release its first quarter 2022 financial results on May 5, 2022, after market close. A conference call and webcast will be held that same day at 4:30 p.m. ET to discuss the results and provide corporate updates. The event can be accessed via phone or through the company’s website. Currently, more than 20 candidates utilizing Xencor’s XmAb® technology are in clinical development, with three marketed by partners.
Xencor, Inc. (NASDAQ: XNCR) has presented new data on its preclinical-stage IL-18 and LAG3-targeted IL-15 cytokine programs at the AACR Annual Meeting 2022. The company introduced a decoy-resistant IL18-Fc fusion protein and a LAG-3 targeted IL15/IL15Rα-Fc fusion protein aimed at preferential TIL expansion. Xencor plans to submit an investigational new drug application for XmAb662 later this year, a promising IL12-Fc cytokine with observed anti-tumor activity. These developments aim to enhance cytokine therapeutics' efficacy while reducing systemic toxicity.